ArticleBMJ public health2024
Health and economic impacts of Vaccae vaccination incorporating active case finding in India and South Africa: a modelling study.
Article in BMJ public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractIntroduction: Tuberculosis (TB) is a major global health issue, particularly, in India and South Africa. We aim to evaluate the potential of the new TB vaccine, Vaccae, to enhance TB control by integrating with active case finding (ACF) strategies in these regions. Methods: Using age-structured dynamic models, we projected the epidemiological and economic outcomes of combining Vaccae vaccination with ACF over 27 years. In India, four age-targeted strategies were analysed: (1) adolescent (15 years), (2) adolescent and young adult (AYA, 15-34 years), (3) adult (18-55 years) and (4) elderly (60+ years). In South Africa, strategies were based on HIV status: (1) HIV-targeted, (2) non-HIV and (3) general population. The vaccine efficacy of Vaccae was set at 54.7%, priced at US$120 per course. Outcomes measured included reductions in TB incidence and mortality, prioritised based on budget, incremental cost-effectiveness ratios (ICER) and benefit-cost ratios (BCR). Results: In India, the adult strategy could prevent 8.70 (95% UI: 6.86-11.13) million TB cases and 0.61 (0.39-0.91) million deaths, reducing incidence and mortality by 20.1% (18.7%-23.5%) and 19.0% (17.5%-22.5%), respectively. In South Africa, the general population strategy could avert 0.67 (0.45-0.99) million TB cases and 0.21 (0.15-0.28) million deaths, reducing incidence by 28.1% (26.1%-30.3%) and mortality by 27.0% (23.5%-30.0%). The vaccination budgets for the AYA strategy in India and the HIV-targeted strategy in South Africa were US$14.0 (10.14-23.29) billion and US$0.09 (0.06-0.15) billion, respectively. The ICERs were US$1082 (927-1426) and US$70 (53-123) per disability-adjusted life year averted, and the BCRs were 2.0 (1.6-2.4) and 176 (83.4-255.3), respectively. Thus, the AYA strategy in India and the HIV-targeted strategy in South Africa were the most favourable. Conclusion: Integrating Vaccae vaccination with ACF could significantly enhance TB control in high-burden countries. Policymakers should consider these strategies, with further research needed to confirm the findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.